Cipla Ltd
NSE:CIPLA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 191.5
1 683
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cipla Ltd
Cipla Ltd
Operating Expenses
Cipla Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cipla Ltd
NSE:CIPLA
|
Operating Expenses
-₹121.4B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Expenses
-₹140B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Operating Expenses
-₹285.7B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-11%
|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Operating Expenses
-₹93.9B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Expenses
-₹56.9B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-10%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Operating Expenses
-₹47.9B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cipla Ltd
Glance View
Cipla Ltd. stands as a prominent player in the global pharmaceutical landscape, rooted in its founding vision of accessible healthcare for all. Established in 1935 in India, the company has evolved from its initial focus on producing affordable medicines to becoming a leading provider of generic and specialty pharmaceuticals, over-the-counter products, and active pharmaceutical ingredients (APIs). With a strong commitment to innovation, Cipla allocates a significant portion of its resources to research and development, leading to a robust pipeline of patented and life-saving treatments, particularly in the fields of respiratory, HIV/AIDS, and oncology therapies. This focus on both global markets and local needs has positioned Cipla not only as a trusted brand in India but also as a key player in over 80 countries worldwide. For investors, Cipla represents a compelling opportunity due to its strategic initiatives aimed at sustaining growth amidst challenging market dynamics. The company's impressive financial performance, characterized by steady revenue growth and healthy margins, underscores its operational efficiency and market-leading position. Cipla’s proactive approach to collaborations, licensing agreements, and technological advancements indicates a future that embraces pharmaceutical innovations while maintaining cost-effective solutions. Furthermore, its commitment to sustainability and ethical practices resonates well in today's socially conscious investing landscape. As healthcare demands continue to rise globally, Cipla's mission to enhance access to vital medications stands to benefit both patients and shareholders alike.
See Also
What is Cipla Ltd's Operating Expenses?
Operating Expenses
-121.4B
INR
Based on the financial report for Sep 30, 2024, Cipla Ltd's Operating Expenses amounts to -121.4B INR.
What is Cipla Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-9%
Over the last year, the Operating Expenses growth was -8%. The average annual Operating Expenses growth rates for Cipla Ltd have been -10% over the past three years , -6% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet
